Edwards Lifesciences to buy CASMED for $100m

Edwards Lifesciences expects the FORE-SIGHT technology to complement its HemoSphere hemodynamic monitoring platform. Credit: Edwards Lifesciences Corporation.



  • Edwards Lifesciences to buy CASMED for $100m